2 / 18
Page 29
Notes:
conferenceseries
.com
Volume 8
Journal of Clinical & Experimental Pharmacology
Pharmacology and Medicinal Chemistry 2018
October 18-19, 2018
October 18-19, 2018 Dubai, UAE
International Conference on
18
th
International Conference on
&
Joint Meeting on
Pharmacology and Toxicology
Medicinal and Pharmaceutical Chemistry
Value of pharmacometrics analyses in drug development
Yuying Gao
Certara China, USA
T
he process of drug development is extremely time consuming and costly. It takes approximately 10-12 years and costs
hundreds of millions or billions dollars. Pharmacometrics is the scientific discipline that uses mathematical models based
on biology, pharmacology, physiology, and disease for quantifying the interactions between drugs and patients. Its purpose
is to reduce cost and shorten development time by optimizing the clinical assessment of efficacy and safety. This presentation
highlights the value of pharmacometric analyses in drug development through selected examples.
Biography
Yuying Gao is a trained anesthesiologist and clinical pharmacologist with more than 100 published books, manuscripts and abstracts and 20 years of modeling
and simulation experience in optimizing treatment and bridging strategies, trial designs and drug development decision-making. In 2006, she joined Certara
(formerly Quantitative Solutions) in its infancy and served as director of the Drug Development Consulting Services, general manager of Asia-Pacific region, and
vice president, most recently as President and CEO of Certara Strategic Consulting China. Prior to joining us in 2006, she was senior scientist at the Pharsight
Corporation (now Certara) from 1999 to 2006. During her career in both medical and consulting services, she has established herself as a thought expert in the
field of anesthesiology and pharmacometrics. She has worked with more than 60 pharmaceutical companies and modeled more than 150 compounds in clinical
development. Her work covers all therapeutic areas with recent focus on cardiovascular disease, oncology and neuroscience.
yuying.gao@certara.comYuying Gao, Clin Exp Pharmacol 2018, Volume 8
DOI: 10.4172/2161-1459-C3-034